Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 107Terminated 23Active not recruiting 10Recruiting 4Approved for marketing 2Withdrawn 1Available 1

Sponsor Class

OTHER 8INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Sunitinib × Clear all
NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡